AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH
Diseases of the Digestive System - Liver
What is the purpose of this trial?
The AURORA study will be conducted to confirm the efficacy and safety of cenicriviroc (CVC) for the treatment of liver fibrosis in adult subjects with NASH.
- Ages18 years - 75 years
- Trial withAllergan Sales, Inc.
- Start Date03/25/2018
- End Date07/30/2019
- Last Updated06/03/2020
- Study HIC#2000021152